Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GST-HG161 in Advanced or Metastatic Solid Tumors
NCT04228406Phase 1Unknown
- Sponsor
- Fujian Cosunter Pharmaceutical Co., Ltd.
- Start
- Jul 2019
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GST-HG161 in solid tumor, sponsored by Fujian Cosunter Pharmaceutical Co., Ltd. Primary endpoints: Dose-Limiting Toxicity up to 27 days and Maximum Tolerated Dose up to 27 days. Status: unknown.
02
Drugs
GST-HG161
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04228406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04228406.